Topical repellents vs placebo or no treatment
Adverse events · people living in malaria‐endemic areas
1 finding from 1 review
- no estimate extracted1 study · 47515 participantsGRADE not reported
Findings
What do systematic reviews say?
143 questions · 151 findings · 47 reviews · Infectious Diseases
No studies found 21 · 13.9%GRADE not reported 23 · 15.2%Very low 30 · 19.9%Low 37 · 24.5%Moderate 28 · 18.5%High 12 · 7.9%
Ivermectin vs control
Adverse events · people living in malaria‐endemic areas
It is very uncertain whether ivermectin changes adverse events compared with control (very low certainty).
1 finding from 1 review
- Ivermectin treatment in humans for reducing malaria transmission 2021 · Cochrane Headline outcomes onlyRR 1.63 [1, 2.67]2712 participantsVery low
Intervention not reported
Adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
- Chemotherapy for second‐stage human African trypanosomiasis: drugs in use 2021 · Cochrane Headline outcomes onlyRR 1.01 [0.95, 1.06]1 study · 394 participantsModerate
A single dose of deworming drugs vs placebo
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted4 studies · 744 participantsModerate
Albendazole 400 mg single dose vs albendazole 400 mg multiple doses
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted3 studies · 316 participantsModerate
Albendazole 400 mg single dose vs mebendazole 500 mg single dose
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted5 studies · 1902 participantsLow
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
- Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis 2019 · Cochrane Headline outcomes onlyRR 0.95 [0.61, 1.48]2 studies · 678 participantsModerate
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (high certainty).
1 finding from 1 review
- Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis 2019 · Cochrane Headline outcomes onlyRR 0.94 [0.79, 1.11]4 studies · 1589 participantsHigh
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
- Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis 2019 · Cochrane Headline outcomes onlyRR 1.16 [0.77, 1.74]1 study · 627 participantsModerate
Intervention not reported
Adverse events · people with lymphatic filariasis or communities where lymphatic filariasis is endemic
The intervention showed no clear difference in adverse events (high certainty).
1 finding from 1 review
- Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis 2019 · Cochrane Headline outcomes onlyRR 0.97 [0.84, 1.13]6 studies · 2894 participantsHigh
Intervention not reported
Adverse events · adults and children with amoebic colitis
The intervention probably leads to lower adverse events (moderate certainty).
1 finding from 1 review
- RR 0.65 [0.46, 0.92]8 studies · 477 participantsModerate
Intervention not reported
Adverse events · adults and children with amoebic colitis
1 finding from 1 review
- no estimate extracted3 studies · 1025 participantsVery low
Resistance testing vs no resistance testing
Adverse events · HIV‐positive people
Resistance testing showed no clear difference in adverse events compared with no resistance testing (low certainty).
1 finding from 1 review
- OR 0.89 [0.51, 1.55]4 studies · 808 participantsLow
Intervention not reported
Adverse events · HIV‐positive people
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
- Antihelminthics in helminth‐endemic areas: effects on HIV disease progression 2016 · Cochrane Headline outcomes onlyRR 1.23 [0.53, 2.83]7 studies · 1649 participantsVery low
Praziquantel 40 mg/kg single dose vs 30 mg/kg single dose
Adverse events · people with urinary schistosomiasis
1 finding from 1 review
- no estimate extracted8 studies · 992 participantsLow
Praziquantel 40 mg/kg multiple doses vs single dose
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
- no estimate extracted1 study · 43 participantsVery low
Metrifonate 3 x 7.5 mg/kg given two weeks apart vs placebo
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
- no estimate extracted2 studies · 493 participantsGRADE not reported
Artesunate vs placebo
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
- no estimate extracted2 studies · 276 participantsLow
Praziquantel and artesunate vs praziquantel
Adverse events · people with urinary schistosomiasis
1 finding from 1 review
- no estimate extracted1 study · 156 participantsVery low
Praziquantel 40 mg/kg vs placebo
Adverse events · people with urinary schistosomiasis
1 finding from 1 review
- no estimate extracted9 studies · 1591 participantsLow